[go: up one dir, main page]

MX2009001275A - Método para el tratamiento de disfunción termorreguladora con paroxetina. - Google Patents

Método para el tratamiento de disfunción termorreguladora con paroxetina.

Info

Publication number
MX2009001275A
MX2009001275A MX2009001275A MX2009001275A MX2009001275A MX 2009001275 A MX2009001275 A MX 2009001275A MX 2009001275 A MX2009001275 A MX 2009001275A MX 2009001275 A MX2009001275 A MX 2009001275A MX 2009001275 A MX2009001275 A MX 2009001275A
Authority
MX
Mexico
Prior art keywords
treating
paroxetine
flushes
menopause
hot flashes
Prior art date
Application number
MX2009001275A
Other languages
English (en)
Inventor
Patricia Allison Tewe Richards
Original Assignee
Noven Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39030027&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009001275(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Noven Therapeutics Llc filed Critical Noven Therapeutics Llc
Publication of MX2009001275A publication Critical patent/MX2009001275A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a un método para tratar a un paciente que sufre de una disfunción termoreguladora, especialmente bochornos y brotes asociados con cambios hormonales debido a la menopausia que ocurre naturalmente (ya sea macho o hembra) o debido a una menopausia inducida químicamente o por cirugía; el método también se puede aplicar en el tratamiento de bochornos, brotes, o sudoración nocturna asociados con estados de enfermedad que interrumpen la regulación hormonal normal de la temperatura del cuerpo.
MX2009001275A 2006-08-04 2007-07-31 Método para el tratamiento de disfunción termorreguladora con paroxetina. MX2009001275A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/499,586 US20080033050A1 (en) 2006-08-04 2006-08-04 Method of treating thermoregulatory disfunction with paroxetine
PCT/US2007/017062 WO2008019010A2 (en) 2006-08-04 2007-07-31 Method of treating thermoregulatory disfunction with paroxetine

Publications (1)

Publication Number Publication Date
MX2009001275A true MX2009001275A (es) 2009-04-16

Family

ID=39030027

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009001275A MX2009001275A (es) 2006-08-04 2007-07-31 Método para el tratamiento de disfunción termorreguladora con paroxetina.

Country Status (27)

Country Link
US (7) US20080033050A1 (es)
EP (2) EP2068881B1 (es)
JP (2) JP5846717B2 (es)
KR (3) KR20140098865A (es)
CN (1) CN101505759A (es)
AU (1) AU2007282065B2 (es)
BR (1) BRPI0715087A2 (es)
CA (1) CA2659577C (es)
CY (2) CY1120867T1 (es)
DK (2) DK2719385T3 (es)
ES (2) ES2698207T3 (es)
HR (2) HRP20181893T1 (es)
HU (2) HUE040481T2 (es)
IL (1) IL196844A (es)
LT (2) LT2068881T (es)
ME (1) ME00592B (es)
MX (1) MX2009001275A (es)
NO (1) NO343176B1 (es)
NZ (1) NZ574735A (es)
PL (2) PL2719385T3 (es)
PT (2) PT2719385T (es)
RS (2) RS58046B1 (es)
RU (1) RU2478379C2 (es)
SG (1) SG176452A1 (es)
SI (2) SI2719385T1 (es)
UA (1) UA96770C2 (es)
WO (1) WO2008019010A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080033050A1 (en) 2006-08-04 2008-02-07 Richards Patricia Allison Tewe Method of treating thermoregulatory disfunction with paroxetine
US9211290B2 (en) * 2012-12-31 2015-12-15 Noven Therapeutics, Llc Solid dispersions of amorphous paroxetine mesylate
JP6038416B1 (ja) * 2015-04-07 2016-12-07 株式会社明治 火照り抑制剤
KR102817311B1 (ko) 2016-09-29 2025-06-09 (주)아모레퍼시픽 젖산을 유효성분으로 포함하는 열성홍조 개선용 건강식품 조성물

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
GB8520154D0 (en) * 1985-08-10 1985-09-18 Beecham Group Plc Chemical process
DE3688827T2 (de) * 1985-10-25 1994-03-31 Beecham Group Plc Piperidinderivat, seine Herstellung und seine Verwendung als Arzneimittel.
GB8714707D0 (en) * 1987-06-23 1987-07-29 Beecham Group Plc Chemical process
GB9325644D0 (en) * 1993-12-15 1994-02-16 Smithkline Beecham Plc Novel formulation
US5470846A (en) * 1994-01-14 1995-11-28 Sandyk; Reuven Treatment of neurological and mental disorders
JPH0837567A (ja) 1994-07-26 1996-02-06 Olympus Optical Co Ltd 情報記録媒体及び情報再生装置
US5856493A (en) * 1995-02-06 1999-01-05 Smithkline Beecham Corporation Process for making novel form of paroxeting hydrochloride anhydrate
SE9501567D0 (sv) * 1995-04-27 1995-04-27 Astra Ab A new combination
US6548084B2 (en) * 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
JP3882224B2 (ja) * 1996-05-31 2007-02-14 旭硝子株式会社 パロキセチンの製造方法
US5672612A (en) * 1996-09-09 1997-09-30 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
US6638948B1 (en) 1996-09-09 2003-10-28 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
CA2193939C (en) * 1996-12-24 2002-02-12 K.S. Keshava Murthy Useful form of anhydrous paroxetine hydrochloride
GB9700690D0 (en) * 1997-01-15 1997-03-05 Smithkline Beecham Plc Novel process
GB9710004D0 (en) * 1997-05-17 1997-07-09 Knoll Ag Chemical process
US5910319A (en) * 1997-05-29 1999-06-08 Eli Lilly And Company Fluoxetine enteric pellets and methods for their preparation and use
NZ501285A (en) * 1997-05-29 2001-10-26 Smithkline Beecham Corp Process for preparing 4-(4'-fluorophenyl)-3-(3', 4'-methylenedioxy-phenyl)-piperidine
TR199903025T2 (xx) * 1997-06-10 2000-07-21 Synthon B.V. 4-Fenilpiperidin bile�imleri.
US5955475A (en) * 1997-06-30 1999-09-21 Endo Pharmaceuticals Inc. Process for manufacturing paroxetine solid dispersions
SE9900190D0 (sv) * 1999-01-22 1999-01-22 Astra Ab New compounds
SE9702799D0 (sv) * 1997-07-25 1997-07-25 Astra Ab New compounds
US6133277A (en) * 1997-12-05 2000-10-17 Janssen Pharmaceutica N.V. (Benzodioxan, benzofuran or benzopyran) derivatives having fundic relaxation properties
EA200000890A1 (ru) 1998-03-02 2001-02-26 Эли Лилли Энд Компани Гидрохлорид флуоксетина для уменьшения "приливов" (приступообразных ощущений жара (при климактерическом синдроме))
HUP0101215A3 (en) * 1998-03-16 2002-05-28 Smithkline Beecham Plc Chrystalline form of paroxetine
US6699882B2 (en) * 1998-03-24 2004-03-02 Smithkline Beecham P.L.C. Paroxetine compositions
US20030028027A1 (en) * 1998-04-09 2003-02-06 Smithkline Beecham Plc Paroxetine maleate
JP3796351B2 (ja) * 1998-04-13 2006-07-12 住友化学株式会社 パロキセチン塩酸塩無水和物の乾燥方法
US6168805B1 (en) * 1998-05-07 2001-01-02 Endo Pharmaceuticals, Inc. Aqueous process for manufacturing paroxetine solid dispersions
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
ES2138937B1 (es) * 1998-07-07 2000-10-01 Medichem Sa Polimorfo de maleato de paroxetina y formulaciones farmaceuticas que lo contienen.
ES2159260B1 (es) * 1999-06-22 2002-05-01 Smithkline Beechan Plc Nueva composicion de metanosulfonato de paroxetina
US6369051B1 (en) * 2000-07-06 2002-04-09 American Home Products Corporation Combinations of SSRI and estrogenic agents
US6660298B1 (en) * 2000-07-27 2003-12-09 Pentech Pharmaceuticals, Inc. Paroxetine tablets and capsules
AU2001296084A1 (en) * 2000-08-28 2002-03-13 Synthon B.V. Paroxetine compositions and processes for making the same
US6498184B2 (en) * 2000-12-05 2002-12-24 Akzo Nobel N.V. Serotonergic compound for a method of treatment of hot flushes in post-menopausal women
DE60107292T2 (de) * 2001-01-04 2005-12-01 Ferrer Internacional S.A. Verfahren zur Herstellung von (+)-trans-4-p-Fluorophenyl-3-hydroxymethyl-1-methylpiperidin
DE20100529U1 (de) 2001-01-11 2001-05-10 Synthon Bv Pharmazeutische Tablette umfassend Paroxetinmesylat
NL1017421C2 (nl) * 2001-02-21 2002-01-15 Synthon Bv Werkwijze voor het vervaardigen van paroxetine.
EP1266659A1 (en) 2001-06-11 2002-12-18 Pantarhei Bioscience B.V. Pyridoxal in combination with serotonin re-uptake inhibitor for the treatment of hot flushes
US6956121B2 (en) * 2002-03-01 2005-10-18 Teva Pharmaceutical Industries Ltd. Preparation of paroxetine involving novel intermediates
MXPA05001705A (es) * 2002-08-14 2005-04-19 Pharmacia & Upjohn Co Llc Uso de reboxetina para el tratamiento de sofocos.
US20040152710A1 (en) 2002-10-15 2004-08-05 Deecher Darlene Coleman Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
ITMI20022344A1 (it) * 2002-11-05 2004-05-06 Biofarm Srl Prodotto in pellicola a rapida dissoluzione in acqua, per il trattamento del latte con batteri e/o enzimi.
TWI267838B (en) * 2003-01-03 2006-12-01 Lite On It Corp Method to detect the type of optical disk
US20050130987A1 (en) 2003-10-14 2005-06-16 Wyeth Methods of treating vasomotor symptoms
KR20070034129A (ko) * 2004-07-22 2007-03-27 와이어쓰 신경계 질환 및 장애의 치료 방법
US20060020015A1 (en) * 2004-07-22 2006-01-26 Wyeth Method for treating nervous system disorders and conditions
US20060100263A1 (en) * 2004-11-05 2006-05-11 Anthony Basile Antipyretic compositions and methods
KR100764679B1 (ko) 2005-07-22 2007-10-09 익수제약 주식회사 파록세틴을 함유하는 경피투여용 패취제
CN101325944B (zh) * 2005-10-11 2013-01-16 耶路撒冷希伯来大学伊萨姆研究开发公司 用于鼻部给药的组合物
US20080033050A1 (en) 2006-08-04 2008-02-07 Richards Patricia Allison Tewe Method of treating thermoregulatory disfunction with paroxetine

Also Published As

Publication number Publication date
RS57980B1 (sr) 2019-01-31
JP5846717B2 (ja) 2016-01-20
ES2698207T3 (es) 2019-02-01
NZ574735A (en) 2011-03-31
WO2008019010A3 (en) 2008-12-24
EP2068881A2 (en) 2009-06-17
LT2719385T (lt) 2018-12-27
JP5895009B2 (ja) 2016-03-30
CA2659577C (en) 2015-11-24
PT2719385T (pt) 2018-12-04
PL2068881T3 (pl) 2019-04-30
SG176452A1 (en) 2011-12-29
SI2068881T1 (sl) 2019-01-31
UA96770C2 (uk) 2011-12-12
BRPI0715087A2 (pt) 2015-02-10
PL2719385T3 (pl) 2019-06-28
US20090275615A1 (en) 2009-11-05
SI2719385T1 (sl) 2019-01-31
RS58046B1 (sr) 2019-02-28
KR20140098865A (ko) 2014-08-08
CN101505759A (zh) 2009-08-12
US20170165251A1 (en) 2017-06-15
KR20150132888A (ko) 2015-11-26
US20200268733A9 (en) 2020-08-27
KR20090040453A (ko) 2009-04-24
US8946251B2 (en) 2015-02-03
HUE040481T2 (hu) 2019-03-28
ME00592A (en) 2011-12-20
CY1120902T1 (el) 2019-12-11
WO2008019010A2 (en) 2008-02-14
HRP20181925T1 (hr) 2019-01-11
IL196844A (en) 2015-11-30
DK2719385T3 (en) 2018-12-10
EP2068881A4 (en) 2009-09-30
EP2719385B1 (en) 2018-08-29
JP2009545593A (ja) 2009-12-24
EP2068881B1 (en) 2018-08-22
AU2007282065B2 (en) 2013-05-09
US20150335631A1 (en) 2015-11-26
US20140249182A1 (en) 2014-09-04
HUE040099T2 (hu) 2019-02-28
LT2068881T (lt) 2018-12-10
US8658663B2 (en) 2014-02-25
US20180036299A1 (en) 2018-02-08
EP2719385A1 (en) 2014-04-16
RU2009107739A (ru) 2010-09-10
US20140235674A1 (en) 2014-08-21
AU2007282065A1 (en) 2008-02-14
JP2014077023A (ja) 2014-05-01
HRP20181893T1 (hr) 2019-01-11
ES2699298T3 (es) 2019-02-08
CA2659577A1 (en) 2008-02-14
US8859576B2 (en) 2014-10-14
US20080033050A1 (en) 2008-02-07
IL196844A0 (en) 2009-12-24
US9393237B2 (en) 2016-07-19
PT2068881T (pt) 2018-11-29
DK2068881T3 (en) 2018-12-10
ME00592B (me) 2011-12-20
NO343176B1 (no) 2018-11-26
NO20090639L (no) 2009-02-25
RU2478379C2 (ru) 2013-04-10
CY1120867T1 (el) 2019-12-11

Similar Documents

Publication Publication Date Title
WO2007112052A3 (en) Formulations and methods for vascular permeability-related diseases or conditions
WO2010126626A3 (en) Dual mechanism inhibitors for the treatment of disease
PH12013500892B1 (en) Composition for use in the prevention and\or treatment of skin conditions and skin diseases
WO2008156685A3 (en) Tendon stem cells
WO2008067121A3 (en) Methods of treating cognitive impairment and dementia
WO2006083533A3 (en) Compositions and methods for inhibiting drusen formation and for diagnosing or treating drusen-related disorders
PT1773361E (pt) Composição baseada em bactérias probióticas e sua utilização na prevenção e/ou tratamento de patologias e/ou infecções respiratórias e na melhoria da funcionalidade intestinal
EP1805156A4 (en) PREPARATION AND USE OF BIPHENYL-4-YL-CARBONYLAMINO-ACID DERIVATIVES FOR THE TREATMENT OF OBESITAS
TW200602045A (en) Amino-5, 5-diphenylimidazolone derivatives for the inhibition of β-secretase
PL2200616T3 (pl) Inhibitory MIPO do leczenia choroby Huntingtona i zaniku wieloukładowego
MX2010002617A (es) Implantes lagrimales y metodos relacionados.
WO2008021210A3 (en) Methods and compositions for the treatment of neurodegenerative disorders
WO2011025938A3 (en) Raf inhibitor compounds and methods of use thereof
EP1740178A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT, PREVENTION OR MANAGEMENT OF SLEEP DISORDERS AND SLEEP DISORDERS ASSOCIATED WITH A DISEASE
WO2009111278A3 (en) Raf inhibitor compounds and methods of use thereof
WO2010151755A3 (en) TREATMENT OF INFLAMMATORY DISEASES USING miR-124
WO2010130785A3 (en) Novel use of probiotics
LT2100508T (lt) Augalų ligų kontrolės kompozicija ir būdas skirtas augalų ligų prevencijai ir kontrolei
SG178900A1 (en) Raf inhibitor compounds and methods of use thereof
WO2008073463A3 (en) Methods and compositions for treating and monitoring treatment of il-13-associated disorders
IL197934A (en) History of hydrobenzamide as hsp90 inhibitors and their use in the treatment of disease
MX2009001275A (es) Método para el tratamiento de disfunción termorreguladora con paroxetina.
NO20085051L (no) Behandling av gastrointestinale forstyrrelser med CGRP-antagonister
FR2901467B1 (fr) Prothese anatomique pour le traitement des hernies, telles que hernies inguinales et crurales et autres
WO2008063746A8 (en) Method of treatment for inflammatory bowel disease